| Date | Title | Description |
| 03.05.2024 | Novo Nordisk rides weight loss drug boom as risks mount | figcaption>span]:font-sans">
Novo Nordisk, the maker of Ozempic and Wegovy, continues to enjoy booming sales, but supply constraints and pricing concerns are putting pressure on the stock.
Why it matters: The company's weight-los... |
| 02.05.2024 | Senators call on Schumer to hold insulin vote | figcaption>span]:font-sans">
Senators backing legislation to cap the cost of insulin in the commercial market and for the uninsured are calling on Senate Majority Leader Chuck Schumer to bring it up for a vote this year.
Why it m... |
| 01.05.2024 | Wall Street stocks fall as markets weigh strong wage data, Fed meeting | U.S. MarketsWall Street stocks fall as markets weigh strong wage data, Fed meeting
By Chibuike OguhApril 30, 202410:54 PM UTCUpdated ago
Save
Text
Small Text
Medium Text
Large Text
Share
Twitter
Facebook
Linkedin
Email
Link
SummaryCompanies... |
| 30.04.2024 | Lilly Reports First-Quarter 2024 Financial Results and Raises Full-Year Revenue Guidance by $2 Billion, Highlights Pipeline Momentum | Revenue in Q1 2024 increased 26%, driven by Mounjaro, Zepbound, Verzenio and Jardiance.
Pipeline progress included positive results from two Phase 3 trials of tirzepatide for obstructive sleep apnea; submission of mirikizumab for Crohn's di... |
| 30.04.2024 | NIIMBL announces 63 students for the 2024 NIIMBL eXperience | NEWARK, Del., April 30, 2024 /PRNewswire/ -- The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NII... |
| 30.04.2024 | Innovent Announces the Appointment of Dr. Samuel Zhang as Global Chief Business Officer (CBO) | SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 27.04.2024 | India becoming attractive for clinical trials, says pharma industry leaders | - |
| 24.04.2024 | Pharma exports rise around 10% to $27.9 billion, US biggest importer | - |
| 24.04.2024 | Govt expands committee for drugs, medical devices pricing reforms | - |
| 24.04.2024 | DATAcc by DiMe Launches Core Measures for Sleep | Core sleep measures and resources will help transform sleep research and care to advance the treatment of multiple disease areas
BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) b... |
| 22.04.2024 | Health | Ozempic ‘oops’ babies spark debate about weight-loss shot use as fertility drugs | Madison Muller | Bloomberg News (TNS)
A surprising thing is happening to some women on weight-loss drugs who’ve struggled with fertility issues: They’re getting pregnant. That’s leading to questions about the safety of medications from Novo... |
| 19.04.2024 | Events showcase IU’s international collaborations in health equity, research and practices | Indiana University’s three decades of leadership in establishing equitable global health partnerships, such as the AMPATH partnership in Kenya, has resulted in improved health and well-being in underserved communities globally thanks to rob... |
| 18.04.2024 | Eli Lilly's weight-loss drug Zepbound could treat sleep apnea | Eli Lilly said Wednesday that its weight-loss drug Zepbound improved symptoms in two late-stage trials of patients with obstructive sleep apnea.
Why it matters: If treating sleep apnea ultimately earns an FDA green light, it could expand in... |
| 17.04.2024 | Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too | Health Another perk of weight-loss drugs? Eli Lilly's Zepbound may alleviate sleep apnea, too
Hilary Brueck
2024-04-17T10:15:02Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email icon An envelope. I... |
| 16.04.2024 | Innovent Announces the Appointment of Dr. Nageatte Ibrahim as the Oncology Chief Medical Officer (CMO) | SAN FRANCISCO and SUZHOU, China, April 16, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 15.04.2024 | Women of Influence: Health Care 2024 – Ileana Hernandez | - |
| 11.04.2024 | Fujifilm Diosynth to add 680 more jobs at Holly Springs biomanufacturing facility | Fujifilm Diosynth will invest $1.2 billion and create an additional 680 jobs at its under-construction biomanufacturing facility in Holly Springs by 2031, the N.C. Department of Commerce announced Thursday morning.
The Japanese contract dru... |
| 08.04.2024 | Biocon leads India's push into anti-obesity drugs as patents lapse | Biocon Ltd. is pivoting to anti-obesity therapies as patents for the blockbuster medications start to expire, unleashing a wave of generic supply for the market that’s expected to touch $100 billion by 2030.
The Bengaluru-based firm has sco... |
| 08.04.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, April 8, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 08.04.2024 | EmeritusDX Announces Launch of FDA Approved Therascreen BRAF and KRAS Tests, Expanding Molecular Testing Capabilities | Headquarters in Lake Forest, CA
The Launch Aligns with the Company's Commitment to Personalized Care and Expanding it's Companion Diagnostics Portfolio
LAKE FOREST, Calif., April 8, 2024 /PRNewswire-PRWeb/ -- EmeritusDX, a leading cancer di... |
| 04.04.2024 | The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months | Markets The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months
William Edwards
2024-04-04T14:09:13Z
Share icon An curved arrow pointing ri... |
| 02.04.2024 | Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status | ROCKVILLE, Md. and SUZHOU, China, April 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 02.04.2024 | No degree needed: Lilly hires more than 130 through Skills First program | - |
| 29.03.2024 | Indiana 250: Sue Ellspermann | - |
| 22.03.2024 | Reimagining PharmaCo and HCP Engagement with Digital, Customer-Centric Strategies, Upcoming Webinar Hosted by Xtalks | www.prescriberpoint.com
In this free webinar, learn how the healthcare industry is transitioning towards digital channels for engaging healthcare professionals (HCPs) and moving beyond traditional in-person promotion. Attendees will learn a... |
| 21.03.2024 | Medicare allows coverage of weight-loss drugs for heart conditions | Medicare will allow coverage of new weight-loss drug Wegovy to reduce the risk of heart attack and stroke in enrollees.
Why it matters: Medicare bans coverage of drugs for weight loss, but more enrollees will have access to popular anti-obe... |
| 20.03.2024 | Innovent Announces 2023 Annual Results and Business Updates | A transformative year of strong performance and material innovation progress
ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that d... |
| 20.03.2024 | A California millennial started secretly working 2 remote jobs so he could afford the Mounjaro weight-loss drug. He's on track to make $166,000 this year and says he's lost 45 pounds. | Economy A California millennial started secretly working 2 remote jobs so he could afford the Mounjaro weight-loss drug. He's on track to make $166,000 this year and says he's lost 45 pounds.
Jacob Zinkula
2024-03-20T14:59:49Z
Share icon An... |
| 19.03.2024 | AstraZeneca Joins Radiopharma Deals Spree With $2B Fusion Acquisition | AstraZeneca is following in the footsteps of some of its big pharmaceutical company peers, plunking down $2 billion to acquire its radiopharmaceuticals partner Fusion Pharmaceuticals. More than adding a pipeline of targeted radiation therap... |
| 19.03.2024 | IU lands $20M donation to establish lung cancer research center | - |
| 19.03.2024 | Innovent Announces Primary Endpoint Met in the Second Phase 2 Clinical Trial of IBI302 (anti-VEGF/complement) in Treating Neovascular Age-related Macular Degeneration (nAMD) | ROCKVILLIE, Md. and SUZHOU, China, March 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines f... |
| 17.03.2024 | Zephyr AI Revolutionizes Precision Medicine with $111M Series A Funding | Zephyr AI, a healthcare technology company based in McLean, VA, has secured $111 million in Series A financing to advance its mission of democratizing precision medicine through explainable AI solutions. Backed by Revolution Growth, Eli Lil... |
| 14.03.2024 | Zephyr AI Secures $111M to Democratize Precision Medicine with Explainable AI | What You Should Know:
– Zephyr AI, a healthcare technology company pioneering explainable AI (XAI) for precision medicine, raises $111M in Series A round led by Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group.... |
| 13.03.2024 | Eli Lilly teams with Amazon to offer home delivery of its Zepbound weight-loss drug | Four months after Eli Lilly obtained regulatory approval to sell its diabetes medication under a different name for weight loss, the pharmaceutical giant is teaming up with Amazon to deliver the drug and other medications directly to people... |
| 13.03.2024 | После вмешательства генпрокурора РФ 68 южноуральцев обеспечены лекарствами | - |
| 13.03.2024 | Anxiety Disorder Treatment Market Size and Share Analysis, Trends, Advancements, Growth Forecast, 2030 | Anxiety Disorder Treatment Market
Anxiety Disorder Treatment Market to Reach $15.89 Billion by 2030, driven by the increasing prevalence of anxiety disorders & advancements in treatment options
With increasing awareness, growing prevale... |
| 12.03.2024 | How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay? | Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements.
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral ... |
| 12.03.2024 | Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2024 AACR Annual Meeting | ROCKVILLE, Md. and SUZHOU, China, March 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... |
| 12.03.2024 | How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay? | - |
| 11.03.2024 | Lilly jabs at people who use new weight-loss drugs ‘for vanity’ | - |
| 11.03.2024 | Nitrase Therapeutics Unveils Pioneering Antibody Candidate for Parkinson’s Disease Based on Nitration Discovery in Oral Presentation at the Alzheimer’s Disease and Parkinson’s Disease (AD/PD) Conferen... | -Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic nitrated synuclein
-Advancing development candidate NDC-0524 into IND-enablin... |
| 09.03.2024 | FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer's drug | INDIANAPOLIS, Indiana: Federal regulators put off a decision on whether to approve an Eli Lilly Alzheimer’s drug by making an unusual request to have outside advisers look at the treatment.
Lilly had expected the Food and Drug Administratio... |
| 08.03.2024 | Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7 | Markets Pharmaceutical companies behind weight-loss drugs are slimming down a new target: The Magnificent 7
Dan DeFrancesco
2024-03-08T14:59:48Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
Facebook Email ico... |
| 08.03.2024 | FDA delays action on Lilly's Alzheimer's drug | The Food and Drug Administration is asking outside advisors to review the safety and efficacy of an experimental Alzheimer's drug from Eli Lilly that was expected to be approved in the first quarter of this year.
Why it matters: Donanemab w... |
| 08.03.2024 | Global Emerging Insulin Drug and Delivery Technologies Market Analysis: Smart Pens Unveiled as Fastest-Growing Segment, Predicted to Register CAGR of 12.6% During 2023-2028 | - |
| 08.03.2024 | Eli Lilly's new ad says weight-loss drugs shouldn't be used out of "vanity" | Eli Lilly has a message for people who are taking prescription medications developed for patients with Type 2 diabetes and obesity: Don't take the drugs just because you want to look good.
The message, delivered in a new Hollywood-themed ad... |
| 07.03.2024 | Novo Nordisk Obesity Pill Flashes the Potential to Beat Wegovy in Weight Loss | An experimental Novo Nordisk obesity pill led to weight loss of 13.1% in a clinical trial, topping results posted in studies of the company’s approved injectable medication Wegovy. It’s early days and more testing is needed, but the prelimi... |
| 07.03.2024 | Pancreatic Cancer Drugs Global Market Report 2024 | - |
| 04.03.2024 | Pharmaceutical Manufacturing Market Projected to Grow at 7.8% CAGR, Reaching $863.6 Bn by 2030 | Vantage Market Research | Vantage Market Research
Pharmaceutical Manufacturing Market Size, Share, Industry Trends, Growth, and Opportunities Analysis by 2030 WASHINGTON, D.C, DISTRICT OF COLUMBIA, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- The Global Pharma... |
| 04.03.2024 | Analgesics Market Set to Surge USD 50.7 Bn by 2028 | 6.6% CAGR | Analgesics Market 2024
PORTLAND, OREGON, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- What is analgesic market?
The Analgesics market comprises over-the-counter natural and synthetic non-opioid analgesics (only in approved low doses) ... |
| 04.03.2024 | Head and Neck Cancer Market Size, Trends, Industry Statistics and Latest Insights Till 2034 | BROOKLYN, NY, USA, March 4, 2024 /EINPresswire.com/ -- What is the market for head and neck cancer?
The head and neck cancer market reached a value of US$ 3,252.3 Million in 2023 and expected to reach US$ 7,279.8 Million by 2034, exhibiting... |
| 28.12.2023 | Lilly Completes Acquisition of Point Biopharma | Eli Lilly and Company (NYSE: LLY) acquired POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer.
Lilly’s ... |
| 14.12.2023 | Where plants, animals and people collide: Indiana is positioned to shape the next chapter in bioscience innovation | This past October, the U.S. Department of Commerce Economic Development Administration chose Indiana as one of 31 designated tech hubs across the country. Branded Heartland Bioworks, the designation could translate to millions in funding to... |
| 15.08.2023 | Eli Lilly and Company Completes Acquisition of Versanis Bio | Eli Lilly and Company (NYSE: LLY) announced the completion of its acquisition of Versanis Bio.
Versanis Bio is a Boston, MA-based company leveraging activin biology to develop therapeutics for obesity and cardiometabolic disease.
The acquis... |
| 13.08.2023 | Excellence In Science And Math Runs In The Family | The Geneus Family in Cap and Gown at Olivia Geneus's PhD graduation from SUNY at Buffalo.Photo Credit: Alexander Harold |
| 14.07.2023 | Eli Lilly and Company Acquires Versanis Bio | Eli Lilly and Company (NYSE: LLY), an Indianapolis, IN-based pharmaceutical manufacturing company, acquired Versanis Bio, a Boston, MA-based clinical-stage biopharmaceutical company.
Under the terms of the agreement, which is subject to cus... |
| 15.06.2023 | The CEO of pharma giant Eli Lilly shares 3 ways AI could transform his industry | David Ricks, the CEO of Eli Lilly. Eli Lilly
Redeem now
Sign up for notifications from Insider! Stay up to date with what you want to know.
Subscribe to push notifications
Read next
Healthcare AI Artifical Intelligence
More...
Close icon Tw... |
| 10.05.2023 | The China NMPA Approves TYVYT® (sintilimab injection) in Combination with Bevacizumab and Chemotherapy in Patients with EGFR-mutated Non-squamous NSCLC who Progressed after EGFR-TKI Therapy | ROCKVILLIE, Md. and SUZHOU, China, May 10, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 08.05.2023 | Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer ... | ROCKVILLE, Md. and SUZHOU, China, May 8, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 18.01.2023 | Innovent Announces Inclusion in the China National Reimbursement Drug List (NRDL) of TYVYT in Two New Indications, Olverembatinib for the First Listing, BYVASDA, HALPRYZA and SULINNO in Multiple New I... | ROCKVILLE, Md. and SUZHOU, China, Jan. 18, 2023 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 15.01.2023 | 50 компаний, за акциями которых стоит следить в 2023 году Статьи редакции | Аналитики Bloomberg составили список самых любопытных проектов, торгующихся на фондовых биржах.
4 комментарии
2011 просмотров
Грузовик компании Coca-Cola. Источник: CNN
#акции #год2023... |
| 19.12.2022 | Prescryptive Health Taps Lilly on First-to-Market Value-Based Program to Stabilize Insulin Pricing | What You Should Know: |
| 04.11.2022 | EMPA-KIDNEY trial showed significant benefit of JARDIANCE® (empagliflozin) in reducing kidney disease progression or cardiovascular death by 28% vs. placebo in people living with chronic kidney diseas... | EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice1,2,3 Phase III trial also demonstrated a 14% statistically significant re... |
| 24.07.2022 | Triastek and Eli Lilly partner to 3D print gastrointestinal drugs | Chinese drug 3D printing firm Triastek has announced a partnership with global pharmaceuticals company Eli Lilly to research and develop 3D printed oral drugs for the gastrointestinal tract.
Specifically, the project will leverage Triastek’... |
| 27.06.2022 | Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-line Treatment of Advanced or Metastatic Gastric or Gastroesop... | SAN FRANCISCO and SUZHOU, China, June 27, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 21.06.2022 | Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Chemotherapy as First-Line Treatment for Esophageal Squamous Cell Carcinoma | SAN FRANCISCO, INDIANAPOLIS and SUZHOU, China, June 21, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality ... |
| 28.03.2022 | Innovent and Lilly Expand Strategic Partnership in Oncology | SAN FRANCISCO and INDIANAPOLIS and SUZHOU, China, March 28, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quali... |
| 16.03.2022 | Eli Lilly стала первой фармацевтической компанией, приостановившей поставку продукции в Россию | Американская компания Eli Lilly остановила инвестиции и поставку продукции в Россию, а также клинические испытания в стране. Она стала первой фармацевтической компанией, отказавшейся от экспорта в Россию некоторых лекарств, за исключением ж... |
| 16.03.2022 | Slack отключает клиентов из России, а VK перезапускает «аську»: главное за 16 марта | О главных событиях к утру 16 марта можно прочитать тут. Подписаться на все события по теме можно здесь. Мир
Крупнейший в мире индексный провайдер S&P Dow Jones после 31 марта исключит из своих индексов облигации российских и белорусских... |
| 11.02.2022 | Lilly's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19 | INDIANAPOLIS, Feb. 11, 2022 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for bebtelovimab, an antibody that demonstrates neutralization against the Omicron variant, Eli Lilly an... |
| 10.02.2022 | Cynthia Cardona Elected as President of the Lilly Foundation | INDIANAPOLIS, Feb. 10, 2022 /PRNewswire/ -- The Eli Lilly and Company Foundation, Inc., a tax-exempt organization supported by Eli Lilly and Company (NYSE: LLY), has elected Cynthia Cardona as its president. Additionally, Lilly has selected... |
| 03.02.2022 | Puerto Rico and STEM: where politics and culture collide | When we talk about the impact that Puerto Ricans have had on the fields of science, technology, engineering. and math (STEM) in Latin America, it quickly becomes a complicated discussion. Culturally, linguistically, historically, anthropolo... |
| 03.02.2022 | Lilly Reports Solid Fourth-Quarter and Full-Year 2021 Financial Results, Recent Late-Stage Pipeline Successes Set Up Next Wave of Innovative Medicines for Patients | INDIANAPOLIS, Feb. 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today.
"Lilly had a remarkable year of growth and pipeline success in 2021, despite t... |
| 02.02.2022 | UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents | NEW YORK and INDIANAPOLIS, Feb. 2, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and adolescents living with chronic, non-c... |
| 02.02.2022 | UNICEF and Lilly Collaborate to Help Improve Health Outcomes for 10 Million Children and Adolescents | NEW YORK and INDIANAPOLIS, Feb. 2, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and UNICEF have today announced a new collaboration to help improve health outcomes for 10 million children and adolescents living with chronic, non-c... |
| 28.01.2022 | Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis | INDIANAPOLIS, Jan. 28, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT® (baricitinib) in adults with active systemic lupus erythematosus... |
| 22.01.2022 | Innovent and Eli Lilly and Company Announced Final Clinical Results and Biomarker Analysis of Phase Ib Study of TYVYT® (Sintilimab Injection) Plus Bevacizumab Biosimilar Injection for Advanced Hepatoc... | SAN FRANCISCO and SUZHOU, China, Jan. 22, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 14.01.2022 | Jumpstart Health Launches $55M Venture Fund for Black Founded Health Startups | Marcus Whitney, Jumpstart Health Investors Co-Founder & Partner
What You Should Know:
– Jumpstart Health Investors, announced this week the launch of Jumpstart Nova, the first venture fund to invest in Black founded and led healthcare i... |
| 06.01.2022 | Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications | INDIANAPOLIS and EDMONTON, AB, Jan. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has acquired exclusive rights to Entos Pharmaceuticals' Fusogenix nucleic acid delivery technology to research, develop and commercialize nucleic ... |
| 15.12.2021 | Lilly Highlights Innovation-based Growth Strategy and Pipeline Developments; Announces 2022 Financial Guidance at Investment Community Meeting | INDIANAPOLIS, Dec. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is providing extensive updates across its research and development (R&D) programs to highlight the company's strong pipeline and potential for future growth. ... |
| 13.12.2021 | Lilly Announces 15 Percent Dividend Increase, First-Quarter 2022 Dividend | INDIANAPOLIS, Dec. 13, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has announced a 15 percent increase in its quarterly dividend and declared a dividend for the first quarter of 2022 of $0.98 per share o... |
| 03.12.2021 | Innovent and Lilly Announce Successful Expansion of Sintilimab in China National Reimbursement Drug List to Include Three Additional First-Line Indications | SAN FRANCISCO, INDIANAPOLIS, and SUZHOU, China, Dec. 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality ... |
| 11.11.2021 | US FDA accepts supplemental New Drug Application and grants Priority Review for Jardiance® for adults with heart failure independent of left ventricular ejection fraction | RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 11, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Jardiance® (empagliflozin) 10 mg, which is... |
| 19.10.2021 | Eli Lilly and : Tirzepatide results published in The Lancet show superior A1C and body weight reductions compared to insulin glargine in adults with type 2 diabetes with increased cardiovascular risk | INDIANAPOLIS, Oct. 19, 2021 /PRNewswire/ -- Adults with type 2 diabetes with increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated ins... |
| 14.10.2021 | Eli Lilly and : Lilly Announces Updated Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Presented at ESMO Virtual Plenary and Simultaneously Published in the Annals of Oncology | INDIANAPOLIS, Oct. 14, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the positive Phase 3 monarchE trial evaluating the investigational use of Verzenio® (abemaciclib) in combination with standard a... |
| 07.10.2021 | Eli Lilly and : Loxo Oncology at Lilly Announces Details of Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics | INDIANAPOLIS, Oct. 7, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that preclinical characterization data for two new agents, LOXO-783 and LOXO-435, will... |
| 30.09.2021 | Incyte : OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata | INDIANAPOLIS, Sept. 30, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and BRAVE-AA2), which found once-daily OLUMIANT® (baricitin... |
| 21.09.2021 | Eli Lilly and : Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities | INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for specified series of its outstanding debt securities.
Holders of notes subject... |
| 21.09.2021 | Eli Lilly and : Lilly Announces the Early Tender Results of Its Pending Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities and Removal of t... | INDIANAPOLIS, Sept. 21, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results of its previously announced cash tender offer for specified series of its outstanding debt securities. Lilly also announ... |
| 16.09.2021 | Emergency Use Authorization for Lilly's bamlanivimab and etesevimab administered together expanded to include post-exposure prophylaxis for COVID-19 | |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies –
– Lead program targets Parkinson’s disease and all forms of Gaucher disease –
C... |
| 13.09.2021 | Eli Lilly and : Lilly to Present New Data from Oncology Portfolio at ESMO Congress | INDIANAPOLIS, Sept. 13, 2021 /PRNewswire/ -- New data from various studies of Eli Lilly and Company's (NYSE: LLY) Verzenio® (abemaciclib), Retevmo® (selpercatinib) and CYRAMZA® (ramucirumab) will be presented at the European Society for Med... |
| 13.09.2021 | Lilly to Present New Data from Oncology Portfolio at ESMO Congress | |
| 09.09.2021 | Eli Lilly and : FDA grants Jardiance® Breakthrough Therapy designation for heart failure with preserved ejection fraction | RIDGEFIELD, Conn. and INDIANAPOLIS, Sept. 9, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Jardiance® (empagliflozin) as an investigational treatment for adults with heart fail... |
| 07.09.2021 | Eli Lilly and : Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities | INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $1.5 billion combined aggregate principal amount (the "Tender Cap") of specified ser... |
| 07.09.2021 | Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to "Type 1 Diabetes Camps Initiative" | |
| 07.09.2021 | Eli Lilly and : Lilly Diabetes joins The Leona M. and Harry B. Helmsley Charitable Trust to pledge significant funding to "Type 1 Diabetes Camps Initiative" | INDIANAPOLIS, Sept. 7, 2021 /PRNewswire/ -- Lilly Diabetes will commit nearly $1 million over the next three years in a joint effort with The Leona M. and Harry B. Helmsley Charitable Trust to promote greater access to care and resources an... |
| 07.09.2021 | Lilly Announces Cash Tender Offer for Up to $1.5 Billion Combined Aggregate Principal Amount of Its Outstanding Debt Securities | |
| 01.09.2021 | Salesforce com : Happy Customers Aren't Everything – Employee Satisfaction Is the Catalyst for Growth | A truly valuable customer experience can only grow from a vibrant employee experience.
Aug 31, 20214 min read
How do we achieve sustainable business growth? The thinking used to be that we did it by focusing on customers and their needs. Bu... |
| 27.08.2021 | Eli Lilly and : Landmark trial demonstrates Jardiance® (empagliflozin) is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fr... | RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 27, 2021 /PRNewswire/ -- Full results from the landmark EMPEROR-Preserved phase III trial demonstrated that Jardiance® (empagliflozin) showed an impressive 21% relative risk reduction for the composi... |
